Nasdaq · Common stock
Obsidian Therapeutics (OBX)
$13.86 −$0.12 (−0.86%)
- Day’s range
- $13.16–$14.30
- Volume
- 204,788
OBX price history
OBX closed at $13.86 on Oct. 26, 2026. Over the past year, its daily close ranged from $11.77 on Oct. 16, 2026 to $35.00 on Aug. 10, 2026.
Data table: OBX daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $13.86 |
| Oct. 23, 2026 | $13.98 |
| Oct. 22, 2026 | $13.94 |
| Oct. 21, 2026 | $13.93 |
| Oct. 20, 2026 | $13.25 |
| Oct. 19, 2026 | $11.94 |
| Oct. 16, 2026 | $11.77 |
| Oct. 15, 2026 | $12.20 |
| Oct. 14, 2026 | $12.22 |
| Oct. 13, 2026 | $11.99 |
| Oct. 12, 2026 | $12.79 |
| Oct. 9, 2026 | $13.00 |
| Oct. 8, 2026 | $12.24 |
| Oct. 7, 2026 | $13.20 |
| Oct. 6, 2026 | $13.22 |
| Oct. 5, 2026 | $13.84 |
| Oct. 2, 2026 | $13.59 |
| Oct. 1, 2026 | $13.32 |
| Sept. 30, 2026 | $13.73 |
| Sept. 29, 2026 | $14.58 |
| Sept. 28, 2026 | $13.37 |
| Sept. 25, 2026 | $12.86 |
| Sept. 24, 2026 | $13.41 |
| Sept. 23, 2026 | $15.26 |
| Sept. 22, 2026 | $17.00 |
| Sept. 21, 2026 | $17.33 |
| Sept. 18, 2026 | $17.75 |
| Sept. 17, 2026 | $17.50 |
| Sept. 16, 2026 | $17.15 |
| Sept. 15, 2026 | $17.00 |
| Sept. 14, 2026 | $18.10 |
| Sept. 11, 2026 | $17.80 |
| Sept. 10, 2026 | $17.16 |
| Sept. 9, 2026 | $18.68 |
| Sept. 8, 2026 | $18.73 |
| Sept. 4, 2026 | $16.82 |
| Sept. 3, 2026 | $17.09 |
| Sept. 2, 2026 | $17.00 |
| Sept. 1, 2026 | $17.04 |
| Aug. 31, 2026 | $17.51 |
| Aug. 28, 2026 | $16.30 |
| Aug. 27, 2026 | $17.04 |
| Aug. 26, 2026 | $18.40 |
| Aug. 25, 2026 | $19.00 |
| Aug. 24, 2026 | $18.70 |
| Aug. 21, 2026 | $19.90 |
| Aug. 20, 2026 | $20.19 |
| Aug. 19, 2026 | $20.00 |
| Aug. 18, 2026 | $19.95 |
| Aug. 17, 2026 | $17.54 |
| Aug. 14, 2026 | $17.77 |
| Aug. 13, 2026 | $18.92 |
| Aug. 12, 2026 | $28.00 |
| Aug. 11, 2026 | $32.90 |
| Aug. 10, 2026 | $35.00 |
| Aug. 7, 2026 | $27.50 |
| Aug. 6, 2026 | $28.35 |
| Aug. 5, 2026 | $28.51 |
| Aug. 4, 2026 | $34.00 |
Key figures
- Average daily volume
- 392,246Past 3 months
- Market value
- $856.2M
- Dividend yield
- —
Price change
- 1 month
- +7.78%
What Wall Street says about OBX
In the past 90 days, Wall Street firms published 4 rating or price-target actions on OBX: 4 new ratings.
| Action | Rating | |||
|---|---|---|---|---|
| Leerink Partners | Initiates coverage | Outperform | $32 | |
| William Blair | Initiates coverage | Outperform | — | |
| LifeSci Capital | Initiates coverage | Outperform | $43 | |
| Piper Sandler | Initiates coverage | Overweight | $42 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
- Headquarters
- Cambridge, Mass.
- Listed
- Aug. 4, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about OBX is on the site yet.